Abstract
G-protein-coupled receptors are a major target for the development of new marketable drugs. A growing number of studies have shown that these receptors could bind to their ligands, signal, and be internalized as dimers. Most of the evidence comes from in vitro studies, but recent studies using animal models support an important role for dimerization in vivo and in human pathologies. It is therefore becoming highly relevant to include dimerization in screening campaigns: the increased complexity reached by the ability to target 2 receptors should lead to the identification of more specific hits that could be developed into drugs with fewer side effects. In this review, we have summarized results from a series of studies characterizing the properties of G-protein-coupled receptor dimers using both in vitro and in vivo systems. Since opioid receptors exist as dimers and heterodimerization modulates their pharmacology, we have used them as a model system to develop strategies for the identification of compounds that will specifically bind and activate opioid receptor heterodimers: such compounds could represent the next generation of pain relievers with decreased side effects, including reduced drug abuse liability.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kieffer BL. Recent advances in molecular recognition and signal transduction of active pep-tides: receptors for opioid peptides. Cell Mol Neurobiol. 1995;15:615-635.
George SR, O’Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov. 2002;1:808-820.
Maggio R, Vogel Z, Wess J. Coexpression studies with mutant muscarinic/adrenergic recep-tors provide evidence for intermolecular “cross-talk” between G-protein linked-receptors. Proc Natl Acad Sci USA. 1993;90:3103-3107.
Rios CD, Jordan BA, Gomes I, Devi LA. G-protein receptor dimerization: modulation of receptor function. Pharmacol Ther. 2001;92:71-87.
Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G-protein coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol. 2002;42:409-435.
Bai M. Dimerization of G-protein coupled receptors: roles in signal transduction. Cell Signal. 2004;16:175-186.
Kroeger KM, Pfleger KD, Eidne KA. G-protein coupled receptor oligomerization in neuroen-docrine pathways. Front Neuroendocrinol. 2003;24:254-278.
Marshall FH, Jones KA, Kaupman K, Bettler B. GABA(B) receptors: the first 7TM het-erodimers. Trends Pharmacol Sci. 1999;20:396-399.
Gomes I, Devi LA. Receptor-receptor interactions modulate opioid receptor function. In: Madras BH, Colvis CM, Pollock D, Rutter JL, Shurtleff D, Von Zastrow M, eds. Cell Biology of Addiction. New York, NY: Cold Spring Harbor Laboratory Press; 2005.
Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci. 2001;2:274-286.
Jordan BA, Devi LA. G-protein coupled receptor heterodimerization modulates receptor function. Nature. 1999;399:697-700.
Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;20:RC110.
George SR, Fan T, Xie Z, et al. Oligomerization of mu and delta opioid receptors: generation of novel functional properties. J Biol Chem. 2000;275:26128-26135.
Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of µ and δ opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA. 2004;101:5135-5139.
Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of soma-tostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensiti-zation. J Biol Chem. 2002;277:19762-19772.
Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between µ opioid and α2A-adrenergic receptors. Mol Pharmacol. 2003;64:1317-1324.
Rios C, Gomes I, Devi LA. Interactions between delta opioid receptors and alpha-adrenocep-tors. Clin Exp Pharmacol Physiol. 2004;31:833-836.
Pfeiffer M, Kirscht S, Stumm R, et al. Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem. 2003;278:51630-51637.
Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K. Atomic-force micros-copy: rhodopsin dimmers in native disc membranes. Nature. 2003;421:127-128.
AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein acti-vation and altered receptor sequestration. Nature. 2000;407:94-98.
Abdalla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med. 2001;7:1003-1009.
Abdalla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell. 2004;119:343-354.
Murtra P, Sheasby AM, Hunt SP, De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature. 2000;405:180-183.
King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyper-algesia. Pain. 2005;116:276-288.
Hunyady L, Vauquelin G, Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol Sci. 2003;24:81-86.
Cherfils J, Chabre M. Activation of G-protein Galpha subunits by receptors through Galpha-Gbeta and Galpha-Ggamma interactions. Trends Biochem Sci. 2003;28:13-17.
Urwyler S, Pozza MF, Lingenhoehl K, et al. N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther. 2003;307:322-330.
Cryan JF, Kaupmann K. Don’t worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci. 2005;26:36-43.
Binet V, Brajon C, Le Corre L, Acher F, Pin JP, Prezeau L. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem. 2004;279:29085-29091.
Cryan JF, Kelly PH, Chaperon F, et al. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimi-dine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther. 2004;310:952-963.
Knoflach F, Mutel V, Jolidon S, et al. Positive allosteric modulators of metabotropic gluta-mate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci USA. 2001;98:13402-13407.
Conigrave AD, Franks AH. Allosteric activation of plasma membrane receptors: physiological implications and structural origins. Prog Biophys Mol Biol. 2003;81:219-240.
Suzuki Y, Moriyoshi E, Tsuchiya D, Jingami H. Negative cooperativity of glutamate binding in the dimeric metabotropic glutamate receptor subtype 1. J Biol Chem. 2004;279:35526-35534.
Gao ZG, Kim SG, Soltysiak KA, Melman N, Ijzerman AP, Jacobson KA. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imi-dazoquinoline derivatives. Mol Pharmacol. 2002;62:81-89.
Trankle C, Weyand O, Voigtlander U, et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003;64:180-190.
Gille A, Seifert R. Low-affinity interactions of BODIPY-FL-GTPgammaS and BODIPY-FL-GppNHp with G(i)- and G(s)-proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003;368:210-215.
Lembo PM, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci. 2002;5:201-209.
Cacace A, Banks M, Spicer T, Civoli F, Watson J. An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors. Drug Discov Today. 2003;8:785-792.
Chen L, Zou S, Lou X, Kang HG. Different stimulatory opioid effects on intracellular Ca(2+) in SH-SY5Y cells. Brain Res. 2000;882:256-265.
Yoon SH, Lo TM, Loh HH, Thayer SA. Delta-opioid-induced liberation of Gbetagamma mobilizes Ca2+ stores in NG108-15 cells. Mol Pharmacol. 1999;56:902-908.
Charles AC, Mostovskaya N, Asas K, Evans CJ, Dankovich ML, Hales TG. Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol Pharmacol. 2003;63:89-95.
Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953-990.
Schiller PW, Weltrowska G, Berezowska I, et al. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers. 1999;51:411-425.
Bryant SD, Salvadori S, Cooper PS, Lazarus LH. New delta-opioid antagonists as pharmaco-logical probes. Trends Pharmacol Sci. 1998;19:42-46.
Durocher Y, Perret S, Thibaudeau E, et al. A reporter gene assay for high-throughput screen-ing of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal Biochem. 2000;284:316-326.
Waldhoer M, Fong J, Jones RM, et al. A heterodimer-selective agonist shows in vivo rele-vance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA. 2005;102:9050-9055.
Mesnier D, Baneres JL. Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J Biol Chem. 2004;279:49664-49670.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Gupta, A., Décaillot, F.M., Devi, L.A. (2008). Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development. In: Rapaka, R.S., Sadée, W. (eds) Drug Addiction. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76678-2_32
Download citation
DOI: https://doi.org/10.1007/978-0-387-76678-2_32
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76677-5
Online ISBN: 978-0-387-76678-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
